A partnership led by the Medical Research Council (MRC) has awarded the University of Cambridge £25 million to provide cutting-edge equipment and infrastructure for its clinical research, from imaging single disease cells through to improved targeting of treatments for patients.
AstraZeneca, its global biologics research and development arm, MedImmune, and the University of Cambridge today announce four new collaborations, building on their existing partnership. The latest collaborations reinforce AstraZeneca’s commitment to research in Cambridge following the company’s decision to locate one of its three global R&D centres and its global headquarters in the city that has been home to MedImmune’s biologics research laboratories for 25 years.
New designs revealed as a public consultation is launched.
Specialist hospital move will develop region's world-leading capabilities after £165 million deal approved
Cancer will affect one in three of us at some point in our lives, so research into this disease is vital. Most cancer patients will see their doctor when the disease is already advanced and harder to treat, according to Professor Ashok Venkitaraman, Director of the Medical Research Council (MRC) Cancer Unit in Cambridge.
The new building for the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge was officially opened by Her Majesty the Queen today.
© 2025 University of Cambridge